Regeneron Stock Plunges 11.63% on Mixed Drug Trial Results

On May 30, 2025, Regeneron's stock experienced a significant drop of 11.63% in pre-market trading.

Regeneron's stock price plummeted following the release of mixed results for the drug Itepekimab, which was developed in collaboration with Sanofi. The disappointing outcomes from the clinical trials have raised concerns among investors about the future prospects of this particular drug.

This news has led to a sharp decline in investor confidence, as the mixed results indicate potential challenges in the drug's development and approval process. The market reaction underscores the high stakes involved in pharmaceutical research and development, where positive clinical trial results are crucial for maintaining stock value.